Literature DB >> 15717061

Drug transport to brain with targeted liposomes.

Anita Schnyder1, Jörg Huwyler.   

Abstract

Antibody-conjugated liposomes or immunoliposomes are particulate drug carriers that can be used to direct encapsulated drug molecules to diseased tissues or organs. The present review discusses examples of successful applications of this technology to achieve drug transport across the blood-brain barrier. In addition, information will be provided on practical aspects such as phospholipid compositions of liposomes, antibody coupling technologies, large-scale production of liposomes, and obstacles related to drug loading of the carrier. Prospects of future uses of immunoliposome-based drug delivery systems such as gene therapy of the brain and clinical trials are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717061      PMCID: PMC539328          DOI: 10.1602/neurorx.2.1.99

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  74 in total

1.  Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells.

Authors:  S M Moghimi; H M Patel
Journal:  Biochim Biophys Acta       Date:  1992-06-29

2.  Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time.

Authors:  P S Uster; T M Allen; B E Daniel; C J Mendez; M S Newman; G Z Zhu
Journal:  FEBS Lett       Date:  1996-05-20       Impact factor: 4.124

3.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.

Authors:  D Triguero; J Buciak; W M Pardridge
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

5.  Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo.

Authors:  A Mori; A L Klibanov; V P Torchilin; L Huang
Journal:  FEBS Lett       Date:  1991-06-24       Impact factor: 4.124

6.  Remote loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into liposomes by pH and acetate gradient methods.

Authors:  S H Hwang; Y Maitani; X R Qi; K Takayama; T Nagai
Journal:  Int J Pharm       Date:  1999-03-01       Impact factor: 5.875

7.  Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes.

Authors:  N Shi; R J Boado; W M Pardridge
Journal:  Pharm Res       Date:  2001-08       Impact factor: 4.200

8.  Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.

Authors:  U Herrlinger; C M Kramm; K S Aboody-Guterman; J S Silver; K Ikeda; K M Johnston; P A Pechan; R F Barth; D Finkelstein; E A Chiocca; D N Louis; X O Breakefield
Journal:  Gene Ther       Date:  1998-06       Impact factor: 5.250

9.  Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.

Authors:  D D Lasic; B Ceh; M C Stuart; L Guo; P M Frederik; Y Barenholz
Journal:  Biochim Biophys Acta       Date:  1995-11-01

10.  A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes.

Authors:  S Shahinian; J R Silvius
Journal:  Biochim Biophys Acta       Date:  1995-11-01
View more
  45 in total

Review 1.  Nanoparticulate systems for drug delivery and targeting to the central nervous system.

Authors:  Emanuela Fabiola Craparo; Maria Luisa Bondì; Giovanna Pitarresi; Gennara Cavallaro
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

2.  Mono and dually decorated nanoliposomes for brain targeting, in vitro and in vivo studies.

Authors:  E Markoutsa; K Papadia; A D Giannou; M Spella; A Cagnotto; M Salmona; G T Stathopoulos; S G Antimisiaris
Journal:  Pharm Res       Date:  2013-12-13       Impact factor: 4.200

Review 3.  Targeting anti-HIV drugs to the CNS.

Authors:  Kavitha S Rao; Anuja Ghorpade; Vinod Labhasetwar
Journal:  Expert Opin Drug Deliv       Date:  2009-08       Impact factor: 6.648

4.  Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line.

Authors:  Niladri Chattopadhyay; Jason Zastre; Ho-Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Pharm Res       Date:  2008-05-31       Impact factor: 4.200

Review 5.  Biomaterials for the central nervous system.

Authors:  Yinghui Zhong; Ravi V Bellamkonda
Journal:  J R Soc Interface       Date:  2008-09-06       Impact factor: 4.118

Review 6.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

7.  MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.

Authors:  Xiaoli Liu; Achuthamangalam B Madhankumar; Patti A Miller; Kari A Duck; Susan Hafenstein; Elias Rizk; Becky Slagle-Webb; Jonas M Sheehan; James R Connor; Qing X Yang
Journal:  Neuro Oncol       Date:  2015-10-31       Impact factor: 12.300

8.  Astrocyte-derived endothelin-1 inhibits remyelination through notch activation.

Authors:  Timothy R Hammond; Ana Gadea; Jeff Dupree; Christophe Kerninon; Brahim Nait-Oumesmar; Adan Aguirre; Vittorio Gallo
Journal:  Neuron       Date:  2014-02-05       Impact factor: 17.173

Review 9.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 10.  Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.

Authors:  Muna Aryal; Costas D Arvanitis; Phillip M Alexander; Nathan McDannold
Journal:  Adv Drug Deliv Rev       Date:  2014-01-22       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.